Key statistics
On Tuesday, Vaxcyte Inc (PCVX:NSQ) closed at 54.98, 98.77% above the 52 week low of 27.66 set on Apr 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 55.65 |
|---|---|
| High | 56.44 |
| Low | 54.87 |
| Bid | 42.00 |
| Offer | 55.73 |
| Previous close | 55.57 |
| Average volume | 2.31m |
|---|---|
| Shares outstanding | 141.03m |
| Free float | 140.35m |
| P/E (TTM) | -- |
| Market cap | 7.84bn USD |
| EPS (TTM) | -4.84 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
- Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte Announces Pricing of $550 Million Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
- Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
- Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
- Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
- Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
More ▼
